Amneal Pharmaceuticals (AMRX) Common Equity (2017 - 2026)

Amneal Pharmaceuticals' Common Equity history runs 10 years deep, the most recent figure standing at -$46.0 million for Q1 2026.

• On a quarterly basis, Common Equity rose 65.18% year-over-year to -$46.0 million in Q1 2026; TTM through Mar 2026 was -$46.0 million, a 65.18% increase from a year earlier, with the FY2025 full-year figure at -$71.3 million, up 34.87% from the prior year.
• Common Equity rose to -$46.0 million in Q1 2026 per AMRX's latest filing, from -$71.3 million in the prior quarter.
• Across five years, Common Equity topped out at $407.4 million in Q1 2022 and bottomed at -$132.0 million in Q1 2025.
• The 5-year median for Common Equity is -$46.0 million (2026), against an average of $36.6 million.
• Across the five-year window, Common Equity tumbled 647.26% in 2024 and surged 65.18% in 2026, its largest moves.
• Year by year, Common Equity stood at $184.0 million in 2022, then tumbled by 89.12% to $20.0 million in 2023, then tumbled by 647.26% to -$109.5 million in 2024, then jumped by 34.87% to -$71.3 million in 2025, then soared by 35.55% to -$46.0 million in 2026.
• Per Business Quant, the three latest AMRX Common Equity figures stand at -$46.0 million (Q1 2026), -$71.3 million (Q4 2025), and -$109.5 million (Q3 2025).